

Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Letter]

Nuril Endi Rahman

Social Welfare Study Program, Muhammadiyah Madiun University, Madiun City, Indonesia

Correspondence: Nuril Endi Rahman, Email ner847@ummad.ac.id

Dear editor

We are very interested in the research titled “Adverse Events Following Immunization With Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone” which explores the effectiveness and challenges of vaccinating children affected by the polio outbreak in Sierra Leone.¹ This paper briefly and clearly describes the emergence of the cVDPV2 outbreak in Sierra Leone, which affected children in the country. Besides that, this study uses a mixed-method approach and a dense population to describe the effectiveness of vaccine implementation and the extent to which vaccine implementers achieve success and overcome various obstacles. However, more work is needed to add a medical perspective on AEFI, and provide hypotheses related to adverse events. There is a need for focus group discussion to understand the participants who are vaccinators and to get a more specific sketch and capture a more complete perception of the client.² In addition, an explanation or narrative about of AEFI is needed based on findings in the field, and to reinforce the finding that vaccination has no causal relationship to the occurrence of AEFI. Thus, the public does not need to be afraid to receive vaccines, because it is clear that the cause of adverse symptoms is not caused by vaccination.

Disclosure

The author reports no conflicts of interest in this communication.

References

1. Thomas F, Abiri OT, Kallon JM, et al. Adverse events following immunization with novel oral polio vaccine type 2, and the experience and challenges of reporting in Sierra Leone. *Drug Healthc Pat Saf.* 2024;Volume 16:61–73. doi:10.2147/DHPS.S466039
2. Aslani P, Hamrosi K, Tong V, et al. Consumer opinions on adverse events associated with medicines and vaccines. *Patient Prefer Adher.* 2018; Volume 12:1383–1392. doi:10.2147/PPA.S167396

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug, Healthcare and Patient Safety ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug, Healthcare and Patient Safety editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Publish your work in this journal

Drug, Healthcare and Patient Safety is an international, peer-reviewed open-access journal exploring patient safety issues in the healthcare continuum from diagnostic and screening interventions through to treatment, drug therapy and surgery. The journal is characterized by the rapid reporting of reviews, original research, clinical, epidemiological and post-marketing surveillance studies, risk management, health literacy and educational programs across all areas of healthcare delivery. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-healthcare-and-patient-safety-journal>

<https://doi.org/10.2147/DHPS.S487045>